Kopran share news, announcements and annual reports
NSE: KOPRANBSE: 524280Pharmaceuticals & BiotechnologySmall Cap
Kopran Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 1993 on BSE, Jun 1999 on NSE
Last close ₹242.21up ₹3.16 (1.32%)BSE ₹242.10
Share price at the NSE close on 2 Nov 2026. Previous close ₹239.05.
2 Nov: open ₹240.50, high ₹246.27, low ₹239.00
52-week range of traded prices to 2 Nov 2026
₹107.00Low, 30 Mar 2026₹295.83High, 30 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,171 Cr1,663rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.21
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.24%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.29
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,22,39546.1% delivered
Kopran board meetings
112 filed, newest first. Page 3 of 3.
Jun 2008
24 Jun · Board meeting
To consider and approve Audited Financial Results for the Financial Year (Six months) Ended on March 31, 2008.
Jan 2008
28 Jan · Board meeting
Meeting of the Board of Directors scheduled to be held on January 28, 2008 to consider among various issue including approval of Unaudited Financial Results for the Quarter ended December 31, 2007 (Provisional) has been rescheduled due to non availability of directors and the same will be held on January 31, 2008. There is no change in the agenda items.22 Jan · Board meeting
Wherein the Board will consider and take on record the Unaudited Results for the Quarter Ended on December 31, 2007.3 Jan · Board meeting
Consideration and approval of the audited financial results for the 18 months ended September 30, 2007 at the Board meeting, held on January 03, 2008, was adjourned. The matter would be considered at a Board meeting to be held on January 08, 2008.3 Jan · Board meeting
Kopran Ltd. has informed the Exchange that: The Board of Directors at its meeting held on January 3, 2008 has approved the assignment of its brand SMYLE to Maneesh Pharmaceuticals Ltd. for the consideration of Rs.52.88 crores. A range of more than twenty (20) products covering Oral Care, Pain Management and Baby products are being marketed successfully under the SMYLE brand. Maneesh Pharmaceuticals Ltd. has been distributing and marketing SMYLE range of products since the last two years, Kopran has been receiving Royalty on the sales of SMYLE products. The decision of the Board is a part of the objective to focus on the International business for pharmaceuticals products, both Formulations and Bulk Drugs. The consideration and approval of the audited financial results for the 18 months ended September 30, 2007 at the Board meeting, held on January 03, 2008, was adjourned. The matter would be considered at a Board meeting to be held on January 08, 2008.
Dec 2007
24 Dec · Board meeting
To consider and approve the Audited Financial Results for the extended Financial Year comprising of 18 months period, ended September 30, 2007.
Sep 2007
25 Sep · Board meeting
Kopran Ltd. has informed the Exchange regarding the Outcome of the Board Meeting held on September 21, 2007 as under: The Board of Directors of the Company have accepted the resignations of the following: (1) Mr. H.P.Vyas - Director (2) Mr. Rajesh Kumar Mundra - Company Secretary. Mr. Surendra Somani, Executive Vice Chairman is designated Compliance Officer of the Company at present. The Company further informed that the Company has received approval from the Registrar of Companies Maharashtra, Mumbai for extension of its Financial year from March 31, 2007 to September 30, 2007 vide their dated September 11, 2007. Accordingly the present Financial Year will be for a period of 18 months ending on September 30, 2007.17 Sep · Board meeting
Inter alia to consider and take on record the Audited Financial Results for the Quarter Ended on June 30, 2007.
Jul 2007
2 Jul · Board meeting
Kopran Ltd. has informed the Exchange that the Board of Directors of the Company at their meeting held on June 30, 2007 has approved the allotment of 1244168 Equity Shares to UTI Bank Limited on account of conversion of loan into Equity Shares. The Board of Directors of the Company has accepted the resignations of the following Directors: 1) Mr. Bruno Beuque,2) Mr. Robert D. Petty.
Jun 2007
25 Jun · Board meeting
Wherein among the other matters, interalia to consider and take on record the Audited Results for upto the Quarter ended on March 31, 2007.
Apr 2007
23 Apr · Board meeting
Among the other matters, inter alia to consider and take on record the Unaudited Results for the quarter ended on March 31, 2007
Jan 2007
22 Jan · Board meeting
Meeting on 31 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”